CRISPR Strikes Again: Fat Cells Starve Tumors,A Revolutionary Approach to Cancer Treatment
/0 Comments/in CRISPR, Preclinical Research/by MaxBatiraxcept’s Potential in Combating Prostate Cancer Bone Metastases
/0 Comments/in Preclinical Research/by MaxEcDNA and Prostate Cancer: A New Frontier in Understanding Resistance
/0 Comments/in Preclinical Research/by MaxHydrogel Breakthrough May Improve Cancer Vaccines
/0 Comments/in Immunotherapy, Not PCa related, Preclinical Research/by MaxUMass Scientists Develop Novel Bacteria-Based Cancer Therapy
/0 Comments/in Oncolytic, Preclinical Research/by MaxHarnessing PROTAC Technology: A Novel Approach to Targeting ERG in Prostate Cancer
/0 Comments/in Preclinical Research, PROTACs/by MaxPreclinical: NRM-823, a Breakthrough T-Cell Engager Targeting Advanced Prostate Cancer
/0 Comments/in Immunotherapy, Preclinical Research/by MaxRPT04402 Reactivating PP2A: A Different Approach in Advanced Prostate Cancer Therapy
/0 Comments/in Preclinical Research/by MaxA New Hope for Aggressive Prostate Cancer: Evexomostat’s Potential
/0 Comments/in Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus personalized medicine Pluvicto prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- LYA914: A Novel Oral PROTAC Targeting Androgen Receptor Variants in Prostate Cancer July 30, 2025
- Phase 1/2 Trial for DS-3939a: A Novel TA-MUC1–Directed ADC for Advanced Prostate Cancer and Beyond July 29, 2025
- AI Platform Aims to Revolutionize Cancer Immunotherapy July 28, 2025
- FDA Clears First-in-Human Phase 1 Trial: RV-01 Targeting Solid Tumors July 28, 2025